pcn poster

Poster

Treatment Patterns From OASIS: Observational Study of Long-Acting Injectables in Schizophrenia

OASIS was a 12-month observational study evaluating real-world outcomes of atypical long-acting injectable (aLAI) antipsychotics in patients with schizophrenia. Most patients initiated aL...

10/26/2023

TV-46000—a Long-Acting Subcutaneous Antipsychotic (LASCA) for the Treatment of Schizophrenia: Local Tolerability and Injection Site Reactions

TV-46000 is a long-acting subcutaneous antipsychotic (LASCA) that combines risperidone and an innovative delivery technology in a suspension suitable for subcutaneous administration in th...

10/26/2023

Understanding Patient Profiles among Medicaid Patients with Treatment-resistant Depression Initiated on Esketamine

Real-world data studies on esketamine use for treatment-resistant depression (TRD) in the US have previously focused on commercially-insured patients. In this study of Medicaid beneficiar...

10/26/2023

Understanding Profiles of Patients with Treatment-resistant Depression by Stringency of Health Plan Prior Authorization Criteria for Approval of Esketamine

In the United States, some health plans have more stringent prior authorization (PA) criteria for esketamine insurance coverage for treatment-resistant depression (TRD), requiring more th...

10/26/2023

Understanding the Experiences of Patients With Major Depressive Disorder Treated With Zuranolone: Qualitative Interviews With Participants From the Open-Label SHORELINE Study

Researchers conducted qualitative interviews to understand patients’ experiences with and perceptions of zuranolone, an oral, investigational, once-daily, 14-day treatment course in clini...

10/26/2023

Understanding the Independent Impact of Social Determinants of Health on Resource Utilization and Health Outcomes in Civilian Post-Traumatic Stress Disorder: A Real-World Evidence Analysis

This study assesses the independent impact of social determinants of health and presence of post-traumatic stress disorder on resource utilization and health outcomes in civilians with po...

10/26/2023

The Relationship Between Therapist Adverse Childhood Experiences, Personal Therapy, Resilience, and Treatment Outcomes

A dissertation exploring the relationships between therapist adverse childhood experiences, personal therapy, resilience, therapeutic alliance, and treatment outcomes.

10/26/2023

The Role of Emotion Dysregulation and Pain-endurance in Non-suicidal Self-injury and Disordered Eating Behaviors

This poster shows the interactive relationship between physical pain endurance and emotion dysregulation as predictors for risky behaviors such as NSSI and disordered eating/exercising. ...

10/26/2023

The Use Of The Socially Assistive Robot (SAR) “Pepper” In Prevention And Treatment Of Psychiatric Diseases – Project Descriptions

The poster gives an overview of two projects dealing with the use of new technologies in the prevention and treatment of psychiatric diseases, which will be conducted at the Medical Unive...

10/26/2023

Time Dynamics of Adverse Events of Interest Occurring with Esketamine Nasal Spray and Quetiapine Extended Release: Results from the ESCAPE‑TRD Phase IIIb Trial

This safety analysis evaluated the duration of treatment-emergent adverse events (TEAEs) reported for esketamine nasal spray (ESK-NS) versus quetiapine extended release (QTP-XR) in patien...

10/26/2023

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Poster

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products